Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Decreased by Krilogy Financial LLC

Krilogy Financial LLC reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 58.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,587 shares of the biopharmaceutical company’s stock after selling 2,235 shares during the quarter. Krilogy Financial LLC’s holdings in Alnylam Pharmaceuticals were worth $631,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ALNY. Groupama Asset Managment boosted its holdings in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $369,943,000. AQR Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 295.2% during the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after purchasing an additional 555,759 shares during the period. Finally, Orbis Allan Gray Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $310.58 on Thursday. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $41.44 billion, a price-to-earnings ratio of 181.63 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $238.62 and a 12 month high of $495.55. The firm has a 50 day moving average of $322.14 and a two-hundred day moving average of $383.15.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.65) earnings per share. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the sale, the executive vice president directly owned 23,406 shares of the company’s stock, valued at $7,483,834.44. This represents a 7.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 38,656 shares of company stock valued at $12,370,696. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. Raymond James Financial restated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Weiss Ratings cut shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $472.78.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.